Rituxan (rituximab)

We report a case of minimal change disease presenting with AKI and nephrotic-range proteinuria 3 weeks after B-cell maturation antigen-directed CAR-T cell therapy, ciltacabtagene autoleucel, in a patient with relapsed refractory multiple myeloma. The patient received one dose of rituximab along with a short course of corticosteroid and had complete kidney recovery by week 4 of therapy. This report emphasizes the need for further investigation into the mechanism of kidney toxicity following CAR-T cell therapy, and potential benefits and risks of immunosuppressive therapy in this context.

Although agents such as lenalidomide and Bruton's tyrosine kinase(BTK) inhibitors have demonstrated efficacy in relapsed/refractory (R/R)PVRL, their role in treatment-naïve patients remains unclear. In conclusion, the combination of Orelabrutinib, rituximab, and intravitreal MTX is a feasible therapeutic strategy for PVRL. Our findings may contribute to a potential paradigm shift in the management of this rare disease.

P3, N=239, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial primary completion date: Dec 2026 --> Jan 2026

P3, N=555, Active, not recruiting, Epizyme, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Feb 2027

P2, N=30, Active, not recruiting, Sun Yat-sen University

P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Mar 2026 --> Jun 2026

Even in the era of rituximab-based immunochemotherapy, survival benefits for these patients remain limited. In recent years, with the development of precision assessment tools such as genotyping and advances in research on personalized immunotargeted therapies, the understanding of CD5(+) DLBCL has deepened, offering the prospect of improved treatment outcomes for some patients. To further standardize diagnosis and treatment practices, the Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association and the Lymphoma Expert Committee of China Anti-Cancer Association have organized relevant experts to formulate this consensus, aiming to guide the standardized diagnosis and treatment of CD5(+) DLBCL patients in China.

The patient initially received 2 cycles of rituximab combined with high-dose methotrexate chemotherapy...Subsequently, the regimen was adjusted to 6 cycles of cytarabine combined with temozolomide chemotherapy followed by radiotherapy for the intracranial lesion...Up to the date of follow-up, the patient's condition was stable without recurrence. Combined with literature review, this article discusses the possible mechanisms of the coexistence of dual-subtype DLBCL (clonal evolution or biclonal origin), the potential pathways of temporal muscle metastasis and the impact of subtype differences on treatment response, which provides clinical reference for the diagnosis and individualized treatment of such rare cases.

P2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

P2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

P3, N=300, Active, not recruiting, Kite, A Gilead Company | Recruiting --> Active, not recruiting

P1, N=20, Recruiting, New York Medical College | Trial completion date: Jul 2025 --> Jul 2027 | Trial primary completion date: Jul 2024 --> Jul 2026